EDIL3 is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Gastric Cancer

Abstract

Abstract Epidermal Growth Factor-like repeats and Discoidin I-Like Domains 3 (EDIL3) is a secretory protein that play important roles in embryonic development and various illnesses such as cancer. However, the biological function of EDIL3 in gastric cancer (GC) is still unclear. In this study, the GEPIA, HPA, MethSurv, SMART, STRING, GeneMANIA, LinkedOmics TIMER, TIMER2.0, TISIDB, and RNAactDrug databaseswere used to comprehensively analyze the roles of EDIL3 in GC. To validate the in silico findings, EDIL3 expression was measured in our collected GC tissues. Meanwhile, several in vitro experiments were performed to test the function of EDIL3 in GC. We found that EDIL3 was highly expressed in GC and associated with adverse clinical features. In vitro assays revealed that EDIL3 promotes the proliferation, migration, and invasion of GC cells. The functions of EDIL3 and co-expression genes were significantly associated with extracellular structure organization and extracellular matrix receptor interaction. EDIL3 expression was positively associated with numerous tumour-infiltrating immune cells and their biomarkers. In conclusion, this study demonstrated that EDIL3 might function as an oncogene and is associated with immune infiltration in GC. EDIL3 could be used as a potential therapeutic target for GC.